Skip to main content
. 2006 Mar;50(3):874–879. doi: 10.1128/AAC.50.3.874-879.2006

FIG. 2.

FIG. 2.

Plots of serum HBV DNA reduction at week 4 versus single-dose and steady-state telbivudine pharmacokinetic parameters underlying plasma exposure (Cmax and AUC0-t). Solid and dashed lines, the Emax model-predicted response curves and associated 95% confidence intervals, respectively. The symbols represent the dose groups.